---
document_datetime: 2023-09-21 22:10:07
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/luminity-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: luminity-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.26382
conversion_datetime: 2025-12-27 19:47:13.3486
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Luminity

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                           |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0042/G            | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 26/04/2023                          | 01/06/2023                                  | SmPC                             | The SmPC section 6.5 has been updated as follows: 1.5 ml liquid in clear borosilicate Type I glass vial, closed with a chlorobutyl elastomeric stopper, and sealed with an aluminium crimp seal having a plastic flip-off button. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | B.II.f.z - Stability of FP - Other variation B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation   |            |            |             |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/2350/ 202112 | Periodic Safety Update EU Single assessment - perflutren                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 01/09/2022 | n/a        |             | PRAC Recommendation - maintenance |
| II/0039            | Update of section 4.4 of the SmPC in order to add a new warning on sickle cell anaemia, and update of section 4.8 of the SmPC to include the new ADRs Kounis Syndrome, sickle cell anaemia vaso-occlusive crisis based on reports in the post-marketing setting. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                    | 19/05/2022 | 01/06/2023 | SmPC and PL |                                   |
| IB/0038/G          | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished                                                                                                                                                                                                                                                                                                                                                                                               | 08/02/2022 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|           | product - Tightening of in-process limits B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                   |            |     |         |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------|
| IB/0037/G | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                            | 15/10/2021 | n/a |         |
| IB/0035/G | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished - Other changes to a test procedure | 15/03/2021 | n/a | product |

<div style=\"page-break-after: always\"></div>

|         | (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of   |            |            |                 | specification   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------|
| IA/0036 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/03/2021 | 16/09/2021 | Annex II and PL |                 |
| II/0033 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/09/2020 | 16/09/2021 | SmPC and PL     |                 |

<div style=\"page-break-after: always\"></div>

| IA/0034            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                      | 14/07/2020   | n/a        |                                  |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| IA/0032            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                      | 17/03/2020   | n/a        |                                  |                                   |
| IB/0031            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                   | 12/02/2020   | n/a        |                                  |                                   |
| IAIN/0029/G        | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 20/09/2019   | 24/09/2020 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/2350/ 201812 | Periodic Safety Update EU Single assessment - perflutren                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 05/09/2019   | n/a        |                                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0026            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                  | 11/04/2019   | n/a        |                                  |                                                                                                                                                                                                                                 |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0027             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/02/2019   | 11/03/2019 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                 |
| N/0025             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/05/2018   | 11/03/2019 | PL                               |                                                                                                                                                                                                                                 |
| IB/0024/G          | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.4.a - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Minor change | 14/12/2016   | n/a        |                                  |                                                                                                                                                                                                                                 |
| PSUSA/2350/ 201512 | Periodic Safety Update EU Single assessment - perflutren                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 02/09/2016   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                               |
| R/0021             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/05/2016   | 15/07/2016 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Luminity in the approved indication remains favourable and therefore recommended the renewal of the marketing |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        | authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0020 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/08/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IAIN/0019 | C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities                                                                                                                                                                                                                                                                                                                                                                                          | 14/08/2014 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0018   | Update of section 4.8 of the SmPC, upon request by CHMP following the assessment of the renewal (R/11), to align the list of ADRs with the latest version of the MAH's Company Core Data Sheet (CCDS). The Package leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the annexes and wording in line with the latest QRD template. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 22/05/2014 | 13/05/2015 | SmPC, Labelling and PL | The following terms are included in the Luminity CCDS and are hereby introduced also in the EU SmPC: lip swelling, atrial fibrillation, cardiac ischaemia, supraventricular tachycardia, tongue disorder, hypertonia, loss of consciousness, bronchospasm, decreased oxygenation, hypoxia, rhinitis, upper airway swelling, throat tightness, facial swelling, abnormal vision, eye swelling and facial hypoaesthesia. |
| II/0017/G | This was an application for a group of variations. - To replace the finished product manufacturer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 18/12/2013 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| - To change the manufacturing finished product. - To change the manufacturing finished product. - To add a coating to the is not in contact with the - To replace the manufacturer - To add an alternative blend. - To make changes in the the lipid blend. B.II.b.1.c - Replacement manufacturing site for manufacturing operation(s) release/control, and secondary biol/immunol medicinal forms manufactured by processes B.II.b.3.z - Change in the finished or intermediate B.II.e.6.b - Change in packaging material not product formulation - Change the product information B.II.c.2.d - Change in - Other changes to a test replacement or addition) B.II.c.4.a - Change in pharmacopoeial or novel B.II.b.3.z - Change in   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                     |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0014 | Update of the product SPC. C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH | 24/05/2012 | n/a        |                                  | The variation (Type C.I.8 (a)) concerns a new Pharmacovigilance system as a consequence of the transfer of the Luminity Marketing Authorisation from Bristol-Myers Squibb to Lantheus MI UK Limited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| R/0011  | Renewal of the marketing authorisation.                                                                                                                                       | 23/06/2011 | 13/09/2011 | SmPC, Annex II, Labelling and PL | Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of Luminity remains positive, but considers that its safety profile is to be closely monitored for the following reasons: A number of safety issues have been identified for Luminity, in particular some serious reactions are still occurring and the post marketing studies have provided little or no new information on the likely mechanism of these reactions. In addition, the product has not been on the EU market for almost three years. The product has just been re-introduced on the market on 15 June 2011. Thus, the CHMP decided that the MAH should continue to submit yearly PSURs until otherwise stated. Therefore, based upon the safety profile of Luminity, which requires submission of yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time. |

<div style=\"page-break-after: always\"></div>

| IA/0012/G   | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used   | 14/06/2011   | n/a        | SmPC, Annex II, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007     | Update of Summary of Product Characteristics and Package Leaflet Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 23/07/2009   | 21/08/2009 | SmPC and PL                        | This variation application is submitted following a safety review of serious unlabelled adverse reactions of Luminity. Following a request by the CHMP, the MAH is updating sections 4.2 and 4.4 to include additional safety information on cardiopulmonary reactions and section 4.8 to add ventricular arrhymias (primary ventricular tachycardia and premature ventricular contractions but also ventricular fibrillation asystole and severe respiratory distress. The Package Leaflet has been updated accordingly. In addition the MAH is also updating some contact details of local representatives. |

<div style=\"page-break-after: always\"></div>

| T/0010   | Transfer of Marketing Authorisation                                                                                                                                                  | 12/06/2009   | 27/07/2009   | SmPC, Annex II, Labelling and PL   | Transder of the marketing authorisation from Bristol-Myers Squibb Pharma Belgium Sprl to Lantheus MI UK Ltd.                                                                                                                                                                                                                                                                      |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009  | Update of Detail Description of the Pharmacovigilance System (Pharmacovigilance) Changes to QPPV Update of DDPS (Pharmacovigilance)                                                  | 22/01/2009   | 20/02/2009   | Annex II                           | The Detailed Description of the Pharmacovigilance System has been updated (Version 3.0) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. |
| II/0008  | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                     | 23/10/2008   | 25/11/2008   | SmPC and PL                        | Following a request by the CHMP, the MAH is updating sections 4.2, 4.5 and 5.2 of the SPC to reflect a lack of data in elderly and in patients with either renal or hepatic impairment. The Package Leaflet has been amended accordingly.                                                                                                                                         |
| IB/0006  | IB_19_b_Change in specification of an excipient - addition of new test parameter                                                                                                     | 12/12/2007   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0005  | IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening IB_13_b_Change in test proc. for active substance - other changes (replacement/addition) | 19/11/2007   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0003  | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                     | 20/09/2007   | 29/10/2007   | SmPC and PL                        | This variation application is submitted following assessment of the 1st PSUR. Following a request by the CHMP, the MAH is updating sections 4.2, 4.4 and 4.8 of the Summary of Product Characteristics. The Package Leaflet has been updated accordingly. The MAH has also updated the contact details of the list of local representatives for Romania and                       |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            |                        | Denmark in the Package Leaflet.   |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0004 | IB_38_c_Change in test procedure of finished product - other changes                             | 24/09/2007 | n/a        |                        |                                   |
| N/0002  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/04/2007 | n/a        | PL                     |                                   |
| IA/0001 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size          | 05/01/2007 | 05/01/2007 | SmPC, Labelling and PL |                                   |